Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Communication Services | 8.41% |
| 3 | Technology | 5.7% |
| 4 | Financials | 3.99% |
| 5 | Consumer Discretionary | 2.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Capricor Therapeutics
CAPR
$366M
| – | – |
-41,000
| Closed | -$1.25M |
|
102
C4 Therapeutics
CCCC
$492M
| – | – |
-28,000
| Closed | -$73.6K |
|
103
Ceco Environmental
CECO
$4.19B
| – | – |
-234,000
| Closed | -$13.9M |
|
104
Celcuity
CELC
$4.58B
| – | – |
-4,000
| Closed | -$457K |
|
105
CG Oncology
CGON
$7.07B
| – | – |
-674,000
| Closed | -$44.1M |
|
106
Cummins
CMI
$80.9B
| – | – |
-9,000
| Closed | -$4.84M |
|
|
CNTA
107
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-4,809,000
| Closed | -$191M |
|
108
Cencora
COR
$60.7B
| – | – |
-1,000
| Closed | -$314K |
|
109
Walt Disney
DIS
$186B
| – | – |
-2,401,591
| Closed | -$231M |
|
110
Dianthus Therapeutics
DNTH
$6.21B
| – | – |
-836,000
| Closed | -$70.2M |
|
111
Dyne Therapeutics
DYN
$4.87B
| – | – |
-10,000
| Closed | -$181K |
|
112
Encompass Health
EHC
$11.9B
| – | – |
-3,000
| Closed | -$290K |
|
113
Entegris
ENTG
$22B
| – | – |
-45,500
| Closed | -$5.33M |
|
114
Erasca
ERAS
$6.17B
| – | – |
-18,000
| Closed | -$291K |
|
115
Evolent Health
EVH
$536M
| – | – |
-14,000
| Closed | -$31.9K |
|
|
FISV
116
Fiserv Inc
FISV
$28B
| – | – |
-86,000
| Closed | -$4.8M |
|
117
Flex
FLEX
$40.8B
| – | – |
-78,000
| Closed | -$5.11M |
|
|
FOLD
118
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-16,000
| Closed | -$231K |
|
119
FormFactor
FORM
$8.92B
| – | – |
-56,500
| Closed | -$5.48M |
|
120
GDS Holdings
GDS
$6.58B
| – | – |
-292,000
| Closed | -$11.8M |
|
121
GE HealthCare
GEHC
$33.8B
| – | – |
-3,000
| Closed | -$214K |
|
122
GlobalFoundries
GFS
$26.4B
| – | – |
-105,000
| Closed | -$4.67M |
|
123
Glaukos
GKOS
$10.9B
| – | – |
-2,600
| Closed | -$280K |
|
124
Globus Medical
GMED
$11.7B
| – | – |
-4,000
| Closed | -$345K |
|
|
125
Alphabet (Google) Class C
GOOG
$4.18T
| – | – |
-996,231
| Closed | -$286M |
|
Similar funds
Thomas Steyer's Q2 2026 Portfolio in Review
As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.
- Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
- Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.